Barclays analyst Andrew Mok raised the firm’s price target on Privia Health (PRVA) to $23 from $22 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s “prudence” in accruing performance in capitated contracts and shared savings began to pay off, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health’s Earnings Call Highlights Robust Growth
- Privia Health price target raised to $30 from $28 at Evercore ISI
- Privia Health price target raised to $31 from $30 at Citizens JMP
- Privia Health Reports Strong Q3 2025 Results
- Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating